Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 12/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002700 | 0.89 | MAPK11 (0.50) | MAPK11MAPK14KCNH2TLR7 | |
| SCHEMBL6003990 | 0.89 | MAPK11 (0.47) | MAPK11MAPK14KCNH2HTR2BTLR7 | |
| SCHEMBL6004384 | 0.88 | MAPK11 (0.57) | MAPK11MAPK14KCNH2PIM1 | |
| SCHEMBL4827940 | 0.87 | MAPK11 (0.61) | MAPK11MAPK14KCNH2TLR7ACKR3 | |
| SCHEMBL4763074 | 0.87 | MAPK11 (0.49) | MAPK11MAPK14KCNH2TLR7 | |
| SCHEMBL6003913 | 0.86 | MAPK11 (0.53) | MAPK11MAPK14KCNH2TLR7ACKR3 | |
| SCHEMBL6004379 | 0.86 | MAPK11 (0.51) | MAPK11MAPK14KCNH2TLR7ACKR3 | |
| SCHEMBL6004871 | 0.86 | MAPK11 (0.51) | MAPK11MAPK14KCNH2TLR7ACKR3 | |
| SCHEMBL6003598 | 0.85 | MAPK11 (0.50) | MAPK11MAPK14KCNH2TLR7ACKR3 | |
| SCHEMBL4761930 | 0.85 | MAPK11 (0.51) | MAPK11MAPK14KCNH2TLR7ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | MAPK11 45/4885MAPK14 26/4885KCNH2 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.